At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (10 mg/1000 mg and 5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
In Brief
A Phase 1 clinical trial evaluating 1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, and 2 other interventions for Healthy. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly
Study Details
Timeline
Interventions
Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
Experimental: high dose Empagliflozin/Metformin XR, FDC tablet